QGC 001

Drug Profile

QGC 001

Alternative Names: Amino butane sulfonate disulfure; QGC-011; QGC001; RB 150

Latest Information Update: 29 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CNRS; INSERM; University Paris Descartes
  • Developer Quantum Genomics
  • Class Amines; Aminopeptidases; Antihypertensives; Disulfides; Metalloexopeptidases; Sulfonic acids
  • Mechanism of Action Glutamyl aminopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic heart failure; Hypertension

Most Recent Events

  • 29 Jun 2017 Quantum Genomics plans a phase II trial for Hypertension in USA, in September 2017 (NCT03198793)
  • 15 Dec 2016 Biomarkers information updated
  • 29 Aug 2016 Investigation in Hypertension (Combination therapy) in France (Quantum Genomics pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top